Drugs & Targets FDA grants clearance to ClearPoint Neuro’s SmartFrame Array version 1.1 April 29, 2022Vol.48 No.17
Drugs & Targets ODAC votes unanimously in support of use of randomized data in PI3K inhibitor trials April 22, 2022Vol.48 No.16
Drugs & Targets FDA grants priority review to Enhertu in previously treated HER2-mutant metastatic NSCLC April 22, 2022Vol.48 No.16
Drugs & Targets FDA fast tracks targeted breast cancer immunotherapy Bria-IMT April 15, 2022Vol.48 No.15
Drugs & Targets City of Hope validates Curate Cell Processing System for CAR T-cell therapy April 08, 2022Vol.48 No.14
Drugs & Targets C2i Genomics launches C2inform MRD test for distributed cancer monitoring in Europe April 08, 2022Vol.48 No.14
Drugs & Targets EU CHMP adopts positive opinion for Keytruda plus chemo ± bevacizumab in persistent, recurrent, or metastatic cervical cancer expressing PD-L1 (CPS ≥1) April 01, 2022Vol.48 No.13
Drugs & Targets EU CHMP adopts positive opinion for Cabometyx in radioactive iodine-refractory differentiated thyroid cancer April 01, 2022Vol.48 No.13
Drugs & Targets CHMP adopts positive opinion for Kymriah in relapsed or refractory follicular lymphoma April 01, 2022Vol.48 No.13
